CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 124 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | – | 102 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 102 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 102 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | -100.0% | 102 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 102 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 102 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 102 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 102 | -64.2% | 0.00% | – |
| Q3 2020 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q1 2020 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q4 2019 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q3 2019 | $2,000 | -33.3% | 285 | 0.0% | 0.00% | – |
| Q2 2019 | $3,000 | +50.0% | 285 | +34.4% | 0.00% | – |
| Q1 2019 | $2,000 | -33.3% | 212 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | -25.0% | 212 | 0.0% | 0.00% | – |
| Q3 2018 | $4,000 | -20.0% | 212 | 0.0% | 0.00% | – |
| Q2 2018 | $5,000 | -16.7% | 212 | 0.0% | 0.00% | – |
| Q1 2018 | $6,000 | – | 212 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |